EUVIMEDEUVIMED entdecken
Crossref

The HDAC Inhibitor RM-3-22 Suppresses Triple-Negative Breast Cancer by Uncoupling Autophagy to Drive FSP1-Dependent Ferroptosis

Essha Chatterjee, Biswajit Dey, Santanu Basak, Ram Sharma, Anamika Sharma, Hoshiyar Singh, Vigneshwar Reddy Ashireddygari, Prasad Tammineni, Kunal Nepali, Santosh Kumar Guru

Translational Research · 2026

DOI: 10.1016/j.trsl.2026.06.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Essha Chatterjee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Biological Sciences, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad, Telangana 500037, India; Dept. of Bi…. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Triple Negative Breast Neoplasms, Ferroptosis, Autophagy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) remains one of the difficult subtypes to treat since it holds aggressiveness, a high recurrence rate, and is devoid of targeted therapy options. Taking these challenges into view, we developed RM-3-22, a hydroxamic acid-based histone deacetylase (HDAC) inhibitor, as a new therapeutic entity, particularly to target TNBC. Various experiments were performed using TNBC cell lines and a xenograft mouse model. Results revealed that RM-3-22 exhibited greater cytotoxicity than SAHA, an FDA-approved inhibitor with IC50 values of 6.49, 7.3, and 3.89 μM against MDA-MB-231, BT-549, and 4T1 Cells, respectively. RM-3-22 exhibited a strong anti-metastatic profile, as evidenced by impaired migratory capabilities of TNBC cells and significant disruption of the architecture of TNBC cell 3D spheroids. Furthermore, RM-3-22 suppressed TNBC progression by targeting autophagy and ferroptosis, as evidenced by reduced p62 and FSP1 expression and increased LC3B and ACSL4 expression. Our research explored the key axis where induction of autophagy is required for RM-3-22-mediated FSP1-dependent ferroptosis in the TNBC model. Surprisingly, as far as we know, this study is the first to show that HDAC inhibitors could induce autophagy-dependent ferroptosis as a cell death mechanism to halt TNBC progression. These results were further validated by the effective reduction in tumour growth in the xenograft mouse model. Collectively, RM-3-22 could be a promising alternative inhibitor for TNBC by targeting the autophagy-ferroptosis mechanism(s).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsTriple Negative Breast NeoplasmsFerroptosisAutophagyHydroxamic AcidsHumansAnimalsFemaleCell Line, TumorMiceXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AutophagyFerroptosisHDAC inhibitorNovel anticancer moleculeTNBC

Substanzen

Histone Deacetylase InhibitorsHydroxamic Acids

Autor:innen und Institutionen

  • Dept. of Biological Sciences, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad, Telangana 500037, India; Dept. of Biotechnology and Bioinformatics, Sambalpur University, Jyoti Vihar, Bur…
  • Dept. of Biological Sciences, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad, Telangana 500037, India.
  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan.
  • Department of Animal Biology, School of Life Sciences, University of Hyderabad, 500046, Hyderabad, India.
  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110031, Taiwan. Electronic address: nepali@tmu.edu.tw.
  • Dept. of Biological Sciences, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad, Telangana 500037, India. Electronic address: santoshkumarguru@gmail.com.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Chatterjee, E., Dey, B., Basak, S., Sharma, R., Sharma, A., Singh, H., Ashireddygari, V. R., Tammineni, P., Nepali, K., & Guru, S. K. (2026). The HDAC Inhibitor RM-3-22 Suppresses Triple-Negative Breast Cancer by Uncoupling Autophagy to Drive FSP1-Dependent Ferroptosis. Translational Research. https://doi.org/10.1016/j.trsl.2026.06.010

Vancouver

Chatterjee E, Dey B, Basak S, Sharma R, Sharma A, Singh H, et al. The HDAC Inhibitor RM-3-22 Suppresses Triple-Negative Breast Cancer by Uncoupling Autophagy to Drive FSP1-Dependent Ferroptosis. Translational Research. 2026. doi:10.1016/j.trsl.2026.06.010

BibTeX
@article{Chatterjee2026,
  author = {Chatterjee, Essha and Dey, Biswajit and Basak, Santanu and Sharma, Ram and Sharma, Anamika and Singh, Hoshiyar and Ashireddygari, Vigneshwar Reddy and Tammineni, Prasad and Nepali, Kunal and Guru, Santosh Kumar},
  title = {The HDAC Inhibitor RM-3-22 Suppresses Triple-Negative Breast Cancer by Uncoupling Autophagy to Drive FSP1-Dependent Ferroptosis},
  journal = {Translational Research},
  year = {2026},
  doi = {10.1016/j.trsl.2026.06.010}
}
Kostenlos starten →